ARMA for Postoperative GERD After Sleeve Gastrectomy

Last updated: February 17, 2022
Sponsor: Chinese University of Hong Kong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gastroesophageal Reflux Disease (Gerd)

Esophageal Disorders

Heartburn (Pediatric)

Treatment

N/A

Clinical Study ID

NCT05259579
CRE-2021.553
  • Ages 18-65
  • All Genders

Study Summary

This study is a pilot trial designed to evaluate the safety and efficacy of endoscopic anti-reflux ablation in postoperative gastroesophageal reflux after sleeve gastrectomy

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with reflux symptoms after sleeve gastrectomy and are dependent on orrefractory to PPI treatment
  • Pathological esophageal acid exposure, defined by DeMeester score >14.7 or acidexposure time (AET) >4.2% on pH study

Exclusion

Exclusion Criteria:

  • Primary esophageal motility disorders
  • Sliding hiatal hernia >3cm
  • Narrow gastric sleeve that precludes retroflexion of scope
  • Gastric sleeve stricture
  • Malignancy
  • Pregnancy
  • Patients not fit for general anesthesia
  • Other cases deemed by the examining physician as unsuitable for safe treatment
  • Refusal to participate

Study Design

Total Participants: 15
Study Start date:
February 01, 2022
Estimated Completion Date:
July 31, 2023

Connect with a study center

  • Chinese University of Hong Kong

    Hong Kong,
    Hong Kong

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.